Document is current
Any future updates will be listed below
-
Authors
Daviet, Remi
Aydogan, Gökhan
Jagannathan, Kanchana
Spilka, Nathaniel
Koellinger, Philipp D. http://orcid.org/0000-0001-7413-0412
Kranzler, Henry R. http://orcid.org/0000-0002-1018-0450
Nave, Gideon http://orcid.org/0000-0001-6251-5630
Wetherill, Reagan R. http://orcid.org/0000-0002-1991-6292
-
Funding
Funding for this research was provided by:
Center for Integrated Healthcare, U.S. Department of Veterans Affairs
National Science Foundation (1942917)
U.S. Department of Health & Human Services | NIH | National Institute on Alcohol Abuse and Alcoholism (K23 AA023894)
- License Information
-
More Information
Article History
Received: 27 March 2020
Accepted: 26 January 2022
First Online: 4 March 2022
Competing interests
: H.R.K. is a member of an advisory board for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Entheon Pharmaceuticals; a consultant to Sobrera Pharmaceuticals; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by AbbVie, Alkermes, Dicerna, Ethypharm, Indivior, Lilly, Lundbeck, Otsuka, Pfizer, Arbor, and Amygdala Neurosciences; and is named as an inventor on PCT patent application #15/878,640 entitled: “Genotype-guided dosing of opioid agonists,” filed January 24, 2018. All other authors declare no competing interests.
